Chemoprevention of Recurrent Bladder Cancer
Name of the Trial
Phase IIB/III Randomized Chemoprevention Study of Celecoxib in Patients with Superficial Transitional Cell Carcinoma of the Bladder at High Risk for Recurrence (MDA-ID-99368). See the protocol summary.
Dr. Anita L. Sabichi of the University of Texas M.D. Anderson Cancer Center.
Why This Trial Is Important
Most patients with newly diagnosed bladder cancer have superficial bladder tumors (i.e., tumors that have not spread beyond the lining of the bladder). Patients with superficial bladder cancer can often be cured by surgery. However, the risk of the cancer returning following potentially curative surgery is high.
Celecoxib (Celebrex®), a COX-2 selective non-steroidal anti-inflammatory drug (NSAID), has shown promise in animal studies for the prevention of many cancers (e.g., bladder, colorectal, esophageal, skin, breast, and prostate). It has also been proven to reduce colorectal polyps in patients with familial adenomatous polyposis (FAP), a condition that leads to the development of colorectal cancer. This trial will study the effectiveness of celecoxib in preventing the recurrence of superficial bladder cancer, which is characterized by high levels of the COX-2 enzyme.
"NSAIDs are arguably the most promising chemopreventive agents for epithelial cancers, such as bladder cancer," said Dr. Jaye Viner of the NCI Division of Cancer Prevention. "With this trial, we are exploring the possible benefits of celecoxib in bladder cancer patients who are at high risk for recurrence."
"Superficial bladder cancer often recurs, even after potentially curative surgery and standard follow-up treatment. There is a strong need to develop safe and effective interventions to reduce this risk," added Dr. Viner.
This trial is no longer accepting new patients. To find other clinical trials for bladder cancer, search the NCI database of clinical trials or call the NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). The call is toll free and completely confidential.